Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Top Cited Papers
- 19 November 2010
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 11 (12), 1149-1159
- https://doi.org/10.1016/s1470-2045(10)70261-8
Abstract
No abstract availableThis publication has 48 references indexed in Scilit:
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate CancerClinical Cancer Research, 2009
- Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteinsProceedings of the National Academy of Sciences, 2008
- Fragment-Based Design of Small Molecule X-Linked Inhibitor of Apoptosis Protein InhibitorsJournal of Medicinal Chemistry, 2008
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosisProceedings of the National Academy of Sciences, 2007
- Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737JCI Insight, 2007
- A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2005
- Cell DeathCell, 2004
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958